9742914

Source:http://linkedlifedata.com/resource/pubmed/id/9742914

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003320, umls-concept:C0020792, umls-concept:C0021756, umls-concept:C0027627, umls-concept:C0030705, umls-concept:C0086597, umls-concept:C0332293, umls-concept:C0677874, umls-concept:C0871261, umls-concept:C1704632, umls-concept:C1706817, umls-concept:C2911692
pubmed:issue	3
pubmed:dateCreated	1998-10-14
pubmed:abstractText	To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-2785562, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-3100623, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-3491225, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-3903508, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-7516411, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-7543520, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-7706734, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-7751637, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-7836932, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-7884429, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-8022805, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-8028037, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-8120958, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-8170938, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-8205528, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-8625167, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-8642255, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-8642260, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-8708739, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-8859727, http://linkedlifedata.com/resource/pubmed/commentcorrection/9742914-9136454
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0372354
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	0003-4932
pubmed:author	pubmed-author:RosenbergS ASA, pubmed-author:SteinbergS MSM, pubmed-author:WhiteD EDE, pubmed-author:YangJ CJC
pubmed:issnType	Print
pubmed:volume	228
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	307-19
pubmed:dateRevised	2009-11-18
pubmed:meshHeading	pubmed-meshheading:9742914-Adolescent, pubmed-meshheading:9742914-Adult, pubmed-meshheading:9742914-Aged, pubmed-meshheading:9742914-Child, pubmed-meshheading:9742914-Female, pubmed-meshheading:9742914-Follow-Up Studies, pubmed-meshheading:9742914-Humans, pubmed-meshheading:9742914-Interleukin-2, pubmed-meshheading:9742914-Kidney Neoplasms, pubmed-meshheading:9742914-Male, pubmed-meshheading:9742914-Melanoma, pubmed-meshheading:9742914-Middle Aged, pubmed-meshheading:9742914-Prognosis, pubmed-meshheading:9742914-Remission Induction, pubmed-meshheading:9742914-Time Factors
pubmed:year	1998
pubmed:articleTitle	Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
pubmed:affiliation	Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
pubmed:publicationType	Journal Article, Clinical Trial